[ad_1]
Deciphera Prescription drugs (NASDAQ:DCPH – Get Unfastened File) used to be upgraded through inventory analysts at Jonestrading from a “cling” ranking to a “purchase” ranking in a analysis document issued on Tuesday, Benzinga reviews.
A number of different equities analysts have additionally commented on DCPH. Piper Sandler raised Deciphera Prescription drugs from a “impartial” ranking to an “obese” ranking and boosted their worth goal for the inventory from $18.00 to $23.00 in a analysis document on Monday. Stifel Nicolaus upgraded Deciphera Prescription drugs from a “cling” ranking to a “purchase” ranking and upped their worth goal for the inventory from $14.00 to $20.00 in a analysis observe on Wednesday, August ninth. In the end, HC Wainwright boosted their worth goal on Deciphera Prescription drugs from $25.00 to $30.00 and gave the inventory a “purchase” ranking in a analysis document on Tuesday. One funding analyst has rated the inventory with a promote ranking and 8 have given a purchase ranking to the corporate. Consistent with MarketBeat, Deciphera Prescription drugs at the moment has a mean ranking of “Average Purchase” and a consensus goal worth of $23.63.
Learn Our Newest Analysis File on Deciphera Prescription drugs
Deciphera Prescription drugs Buying and selling Down 1.1 %
Stocks of DCPH opened at $11.86 on Tuesday. The company has a marketplace cap of $934.81 million, a PE ratio of -5.05 and a beta of 0.71. The corporate’s 50 day easy transferring moderate is $12.53 and its 200-day easy transferring moderate is $13.54. Deciphera Prescription drugs has a 12-month low of $9.90 and a 12-month prime of $22.76.
Deciphera Prescription drugs (NASDAQ:DCPH – Get Unfastened File) ultimate launched its income effects on Monday, October thirtieth. The corporate reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) through $0.03. Deciphera Prescription drugs had a unfavourable go back on fairness of 48.99% and a unfavourable web margin of 127.92%. The corporate had earnings of $43.31 million all through the quarter, in comparison to the consensus estimate of $39.66 million. All through the similar quarter ultimate yr, the corporate earned ($0.55) income consistent with percentage. As a gaggle, equities analysis analysts forecast that Deciphera Prescription drugs will put up -2.36 EPS for the present fiscal yr.
Insider Transactions at Deciphera Prescription drugs
In comparable information, CFO Thomas Patrick Kelly bought 2,316 stocks of the trade’s inventory in a transaction on Monday, October thirtieth. The inventory used to be bought at a mean worth of $12.02, for a complete price of $27,838.32. Following the sale, the manager monetary officer now owns 63,068 stocks of the corporate’s inventory, valued at roughly $758,077.36. The sale used to be disclosed in a felony submitting with the SEC, which is to be had via this hyperlink. In different information, CFO Thomas Patrick Kelly bought 2,316 stocks of the trade’s inventory in a transaction on Monday, October thirtieth. The inventory used to be bought at a mean worth of $12.02, for a complete transaction of $27,838.32. Following the final touch of the sale, the manager monetary officer now owns 63,068 stocks within the corporate, valued at $758,077.36. The transaction used to be disclosed in a submitting with the SEC, which is to be had at this link. Additionally, EVP Matthew L. Sherman bought 2,360 stocks of the trade’s inventory in a transaction on Monday, October thirtieth. The inventory used to be bought at a mean worth of $12.02, for a complete price of $28,367.20. Following the sale, the manager vice chairman now owns 90,628 stocks of the corporate’s inventory, valued at roughly $1,089,348.56. The disclosure for this sale can also be discovered right here. Within the ultimate quarter, insiders have bought 30,598 stocks of corporate inventory valued at $369,730. 4.43% of the inventory is owned through company insiders.
Institutional Inflows and Outflows
A number of institutional traders and hedge budget have not too long ago changed their holdings of DCPH. China Common Asset Control Co. Ltd. raised its stake in Deciphera Prescription drugs through 96.9% within the 3rd quarter. China Common Asset Control Co. Ltd. now owns 2,026 stocks of the corporate’s inventory valued at $26,000 after purchasing an extra 997 stocks all through the length. Ameritas Funding Companions Inc. boosted its holdings in stocks of Deciphera Prescription drugs through 25.5% all through the first quarter. Ameritas Funding Companions Inc. now owns 4,149 stocks of the corporate’s inventory valued at $64,000 after obtaining an extra 844 stocks within the ultimate quarter. Compass Wealth Control LLC got a brand new stake in stocks of Deciphera Prescription drugs all through the 4th quarter valued at $70,000. Guide Team Holdings Inc. boosted its holdings in stocks of Deciphera Prescription drugs through 78.0% all through the 4th quarter. Guide Team Holdings Inc. now owns 4,331 stocks of the corporate’s inventory valued at $71,000 after obtaining an extra 1,898 stocks within the ultimate quarter. In the end, Lazard Asset Control LLC purchased a brand new place in Deciphera Prescription drugs all through the first quarter price $57,000. 70.96% of the inventory is owned through institutional traders and hedge budget.
About Deciphera Prescription drugs
Deciphera Prescription drugs, Inc, a biopharmaceutical corporate, develops medication to improve the lives of most cancers sufferers through addressing key mechanisms of drug resistance that restrict the velocity and sturdiness of reaction to current most cancers treatments in the US and across the world. Its lead drug candidate is QINLOCK used for the remedy of gastrointestinal stromal tumors (GIST), in addition to in INTRIGUE Segment 3 find out about to regard second-line GIST.
Advisable Tales
Obtain Information & Rankings for Deciphera Prescription drugs Day by day – Input your electronic mail deal with underneath to obtain a concise day-to-day abstract of the most recent information and analysts’ rankings for Deciphera Prescription drugs and comparable corporations with MarketBeat.com’s FREE day-to-day electronic mail e-newsletter.
[ad_2]
